DMSO Therapy
Patents
Enhancing tissue penetration of physiologically active
steroidal agents with DMSO
Inventor: HERSCHLER ROBERT J
US4177267
1979-12-04
COMPOSITIONS FOR TOPICAL APPLICATION FOR ENHANCING TISSUE
PENETRATION OF PHYSIOLOGICALLY ACTIVE AGENTS WITH DMSO
Inventor: HERSCHLER R
US3711602
1973-01-16
ENHANCING TISSUE PENETRATION OF PHYSIOLOGICALLY ACTIVE
STEROIDAL AGENTS WITH DMSO
Inventor: HERSCHLER R
US3711606
1973-01-16
USE OF TARGETED OXIDATIVE THERAPEUTIC FORMULATION IN TREATMENT
OF VIRAL DISEASES
Inventor: HOFMANN ROBERT
SG135190
2007-09-28
Use of targeted oxidative therapeutic formulation in bone
regeneration
CN101027086
2007-08-29
Use of targeted oxidative therapeutic formulation in treatment
of diabetes and obesity
CN101027087
2007-08-29
Use of targeted oxidative therapeutic formulation in treatment
of burns
CN101010077
2007-08-01
Therapeutic DMSO solvates of
1-[4-hydroxyphenyl]-2-(4-benzylpiperidin-1-yl)-1-propanol
(ifenprodil)
GB2430434
2007-03-28
Use of targeted oxidative therapeutic formulation in
endodontic treatment
US2006035881
2006-02-16
USE OF TARGETED OXIDATIVE THERAPEUTIC FORMULATION IN ENDODONTIC
TREATMENT
WO2006002287
2006-01-05
Use of targeted oxidative therapeutic formulation in treatment
of burns
US2006014732
2006-01-19
Use of targeted oxidative therapeutic formulation in treatment
of cancer
US2005250757
2005-11-10
USE OF TARGETED OXIDATIVE THERAPEUTIC FORMULATION IN TREATMENT
OF CANCER
WO2005110388
2005-11-24
USE OF TARGETED OXIDATIVE THERAPEUTIC FORMULATION IN TREATMENT
OF AGE-RELATED MACULAR DEGENERATION
WO2005110484
2005-11-24
Use of targeted oxidative therapeutic formulation in treatment
of diabetes and obesity
US2005272714
2005-12-08
Use of targeted oxidative therapeutic formulation in treatment
of age-related macular degeneration
US2005250756
2005-11-10
Use of targeted oxidative therapeutic formulation in treatment
of viral diseases
US2005192267
2005-09-01
THERAPEUTIC ANTI-FUNGAL NAIL PREPARATION
MXPA01004908
2003-03-10
TREATMENT OF CARBON MONOXIDE POISONING
WO0122960
2001-04-05
Dimethylformamide and other polar compounds for the treatment
of wasting syndrome and HIV infections
NZ501669
2001-09-28
THERAPEUTIC DIMETHYL SULFOXIDE COMPOSITION AND METHODS OF USE
CA1166575
1984-05-01
PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE PROPHYLAXIS
AND/OR TREATMENT OF CERTAIN DISEASES
CA1115638
1982-01-05
Therapeutic compositions comprising dimethylsulphoxide
GB1122005
1968-07-31
http://www.cancertutor.com/Cancer/DMSO.html
DMSO
No later than 1968, it was discovered that there was another product that could target cancer cells, but this product actually bound to the chemotherapy. In this article (which will be linked to below):
"Haematoxylon [a dye] Dissolved in Dimethylsulfoxide [DMSO] Used in Recurrent Neoplasms [i.e. cancer cells or tumor cells]," by E. J. Tucker, M.D., F.A.C.S., and A. Carrizo, M.D. in International Surgery, June 1968, Vol 49, No. 6, page 516-527
It was shown that DMSO targeted cancer cells!! Is it any wonder that the referee of the article stated:
"In spite of my criticisms, there are some parts of this study which do interest me very much. The fact that the Haematoxylon [a color die, which allowed the researchers to see which cells absorbed the DMSO and haematoxylon] and D.M.S.O. solution had a particular affinity for neoplasms [i.e. cancerous cells], and did not stain other tissues in animals could be most significant."
In other words, these researchers had discovered something that could bind to chemotherapy and then target cancer cells. They had found a second "magic bullet"!!
The combination of DMSO and Haematoxylon was being used as a cure for cancer in this study. The combination performed very, very well. However, it was unfortunate that chemotherapy was used in many of the cases. Since DMSO binds to some types of chemotherapy (which was probably not known at the time), it is not know whether the success of the treatment was caused by the DMSO/chemotherapy combination or the DMSO/haematoxylon combination.
In any case, even though both DMSO and haematoxylon are purely non-toxic and purely natural (both come from trees), this is not a treatment that should be used at home. It can cause severe internal bleeding in some cases. It is far beyond the scope of this article to get into the use of this treatment.
The point is that the "magic bullet" had been found, which this website calls "DMSO Potentiation Therapy (DPT)." Obviously, further research using DMSO and chemotherapy, or DMSO and haematoxylon, never happened.
Why don't you ask your oncologist why research on the magic bullet discovered in 1968 was not followed up on!! You might mention the scientific study discussed above.
In later studies DMSO was found to be a superb potentiator of
Adriamycin, Cisplatin, 5 Fluorouracil, and Methotrexate, and
others. For more information about DMSO and chemotherapy see the
excellent book (which talks about both IPT and DMSO being
combined with chemotherapy):
Treating Cancer With Insulin Potentiation Therapy, by Ross A.
Hauser, M.D. and Marion A. Hauser, M.S.
Absolutely nothing has been done about these discoveries for
almost 40 years!! The complete article discussing DMSO and
Haematoxylon can be found at:
The Original DMSO and Haematoxylon Journal Article
You might ask your oncologist why your chances of survival are only 3% (ignoring all of their statistical gibberish such as "5-year survival rates" and deceptive terms like "remission" and "response"), when your chance of survival would be over 90% if they used DMSO with very small doses of chemotherapy.
It would be better for medical doctors to treat cancer patients with the right treatment than to have patients treat themselves at home. Medical doctors can diagnose better, treat better, watch for developing problems better, etc. Unfortunately, doctors are using treatments that have been chosen solely on the basis of their profitability rather than their effectiveness.
DMSO is a highly non-toxic, 100% natural product that comes from the wood industry. But of course, like IPT, this discovery was buried. DMSO, being a natural product, cannot be patented and cannot be made profitable because it is produced by the ton in the wood industry. The only side-effect of using DMSO in humans is body odor (which varies from patient to patient).
The FDA took note of the effectiveness of DMSO at treating pain and made it illegal for medical uses in order to protect the profits of the aspirin companies (in those days aspirin was used to treat arthritis). Thus, it must be sold today as a "solvent." Few people can grasp the concept that government agencies are organized for the sole purpose of being the "police force" of large, corrupt corporations.
While it is generally believed that orthodox medicine and modern corrupt politicians persecute alternative medicine, this is not technically correct. What they do is persecute ANY cure for cancer, it doesn't matter whether it is orthodox or alternative. The proof of this is IPT and DMSO, which can both be combined with chemotherapy. It appears that orthodox medicine persecutes alternative medicine only because there are far more alternative cancer treatments that can cure cancer than orthodox treatments.
Another substance that targets cancer cells is being researched at Purdue University and other places: folic acid. This too will be buried unless it can lead to MORE PROFITABLE cancer treatments.
But alternative medicine is not interested in combining DMSO with chemotherapy. DMSO will combine with many substances, grab them, and drag them into cancer cells. It will also blast through the blood-brain barrier like it wasn't even there.
DMSO has been combined successfully with hydrogen peroxide (e.g. see Donsbach), cesium chloride, MSM (though it may not bind to MSM), and other products.
(Note: The issue has come up several times whether it would be a good idea to mix DMSO with full-strength chemotherapy. This question generally comes up when someone wants to take cesium chloride and DMSO with their chemotherapy. The theory would lean against such advice, however, in actual practice many patients on chemotherapy have also taken DMSO. It does not seem to cause a problem, but whether the DMSO binds to the chemotherapy would depend on which chemotherapy was being used. DMSO does not bind to every type of chemotherapy, only certain kinds (the exact kinds are not totally known because the FDA forced all research on DMSO to stop).
http://www.newmediaexplorer.org/chris/2003/11/11/dmsothe_king_antioxidant.htm
DMSO-The King Antioxidant
What It Does
DMSO tends to build up white blood cells and increase immune production of MIF (migration inhibitory factors) of macrophages. Thus, the immune system is made more effective by allowing macrophages to move more quickly. Thus DMSO modulates lymphocytes, and it therefore reactivates the production of MIF. It also diminishes allergic reactions by unfolding the cell membrane and making more cell receptor sites available to attachment by specific antigens.
The modulating effect of DMSO on lymphocytes also tends to increase the production of lymphokines (chemical immune cell mediators) such as interferon. It potentiates cell mediated immunity and can be effective in multiple sclerosis, systemic lupus, erythematosus, rheumatoid arthritis, thyroiditis, ulcerative colitis, cancer, etc.
What Are Its Major Therapeutic Properties?
* It blocks pain by interrupting conduction in the small
c-fibers, the non-myelinating nerve fibers.
* It is anti-inflammatory.
* It is anti bacterial, fungal and viral.
* It transports all molecules (drugs, etc.) across cell
membranes.
* It reduces the incidence of platelet thrombi (clots in
vessels).
* It effects cardiac contractility by inhibiting calcium to
reduce the workload of the heart.
* It is a vasodilator, probably related to histamine release in
the cells and to prostaglandin inhibition.
* It softens collagen.
* It is a scavenger of the hydroxyl free radical.
* It stimulates the immune system.
* It is a potent diuretic.
* It increases interferon formation.
* It stimulates wound healing.
Summary
DMSO has certain unique physiological characteristics which stem from its molecular makeup:
* It is a simple small molecule with unusual properties.
* An exothermic reaction occurs when DMSO is diluted with water
(heat is generated).
* Hydroxyl radicals (OH), which are free radicals (oxidants),
are ubiquitous and highly injurious to cells — and thus health.
DMSO neutralizes (quenches) these free radicals. It is a free
radical scavenger!
* DMSO substitutes for water in the living cell—it can destroy
intracellular free radicals. No other antioxidant can do that.
* DMSO increases the permeability of cell membranes yielding a
flushing effect of toxins from intracellular location to
extracellular.
* It is an antidote to allergic reactions.
* It can penetrate any cell wall; thus it can get where most
chemicals can’t.
* It has a very low index of any toxicity.
* Allergic reactions to DMSO can occur but they are uncommon.
* DMSO has a myriad of applications in medicine. Some are so
dramatically effective that the concept of such therapy just
boggles the mind!
References
Szmant, H. Harry. Physical properties of dimethyl sulfoxide and its function in biological systems, Biological Actions of Dimethyl Sulfoxide ed. by Stanley W. Jacob and Robert Herschler. (New York: New York Academy of Sciences, 1975), pp. 20-23.
Barfeld, H., and T. Atoynatan. N-acetylcysteine inactivates migration inhibitory factor and delayed hypersensitivity reactions. Nature new Bio., 231:157-159, 1971.
Barfeld, H., and T. Atoynatan, Cytophilic nature of migration inhibitory factor associated with delayed hypersensitivity, Proc. Soc. Exp. Biol. Med., 139:497-501, 1969.
Tschope, M., cited in Raettig, H. “The potential of DMSO in experimental immunology,” Dimethylsulfoxyl, Internationales Symposium in Wien. G. Laudahn and K. Getrich, eds.; 54. Saladruck, Berlin, Germany, 1966.
Engel, M.F. Ann. N.Y. Acad. Sci., 141:638, 1967.
www.spinalrehab.com.au/updates/DMSO%20-%20Information.htm
DMSO information : Hyperbaric Medicine : Melbourne - Australia
Itching is a common side effect of topical DMSO therapy - this
side effect can usually be avoided by diluting the concentration
of DMSO. ...
http://www.dmso.org/
Dr. Stanley W. Jacob can be contacted at jacobs@ohsu.edu. Dr. Jacob is no longer seeing patients. He is taking this time to write scientific publications and continue his research on DMSO.
Ultra Pure DMSO & MSM can be ordered directly from Dr. Jacob's Laboratory. Contact Dr. Jacob's son, Jeff, by calling toll free 1.866.375.2262 or visit www.jacoblab.com.
http://www.dmso.org/articles/information/herschler.htm
Pharmacology of DMSO
by
Stanley W. Jacob and Robert Herschler
Department of Surgery • Oregon Health Science University •
Portland, Oregon 97201
Abstract
A wide range of primary pharmacological actions of dimethyl sulfoxide (DMSO) has been documented in laboratory studies: membrane transport, effects on connective tissue, anti-inflammation, nerve blockade (analgesia), bacteriostasis, diuresis, enhancements or reduction of the effectiveness of other drugs, cholinesterase inhibition, nonspecific enhancement of resistance to infection, vasodilation, muscle relaxation, antagonism to platelet aggregation, and influence on serum cholesterol in emperimental hypercholesterolemia. This substance induces differntiation and function of leukemic and other malignant cells. DMSO also has prophylactic radioprotective properties and cryoprotective actions. It protects against ischemic injury. (1986 Academic Press, Inc.)
The pharmacologic actions of dimethyl sulfoxide (DMSO) have stimulated much research. The purpose of this report is to summarize current concepts in this area.
When the theorectical basis of DMSO action is described, we can list literally dozens of primary pharmacologic actions. This relatively brief summary will touch on only a few:
(A) membrane penetration
(B) membrane transport
(C) effects on connective tissue
(D) anti-inflamation
(E) nerve blockade (analgesia)
(F) bacteriostasis
(G) diuresis
(H) enhancement or reduction of effectiveness
of other drugs
(I) cholinsterase inhibition
(J) nonspecific enhancement of resistance of
infection
(K) vasodilation
(L) muscle relaxation
(M) enhancement of cell differentiation and
function
(N) antagonism to platelet aggregation
(O) influence on serum cholesterol in
experimental hypercholesterolemia
(P) radio-protective and cryoprotective
actions
(Q) protection against ischemic injury
Primary Pharmocological Actions
A. Membrane Penetration
DMSO readily crosses most tissue membranes of lower animals and man.
Employing [35S] DMSO, Kolb et al,59 evaluated the absorption and distribution of DMSO in lower animals and man. Ten minutes after the cutaneous application in the rat, radioactivity was measured in the blood. In man radioactivity appeared in the blood 5 minutes after cutaneous application. One hour after application of DMSO to the skin, radioactivity could be detected in the bones.
Denko22 and his associates applied 35S-labeled DMSO to the skin of rats. Within 2 hour a wide range of radioactivity was distributed in all organs studied. The highest values occurred in decreasing order in the following soft tissues; spleen, stomach, lung, vitreous humor, thymus, brain, kidney, sclera, colon, heart, skeletal muscle, skin, liver, aorta, adrenal, lens of eye, and cartilage.
Rammler and Zaffaroni80 have reviewed the chemical properties of DMSO and suggested that the rapid movement of this molecule through the skin, a protein barrier, depends on a reversible configurational change of the protein occurring when DMSO substitutes for water.
B. Membrane Transport
Nonionized molecules of low molecular wight are transported through the skin with DMSO. Substance of high molecular weight such as insulin do not pass through the skin to any significant extent. Studies in our laboratory have revealed that a 90% concentration of DMSO is optimal for the passage of morphine sulfate dissoved in DMSO.77 It would have been expected that 100% would provide better transport than 90%, and the reason for an optimal effect at 90% DMSO remains unexplained. It is of course well known that 70% alcohol has a higher phenol:water partition coefficient than 100% alcohol.
Elfbaum and Laden27 conducted an in vitro skin penetration study employing guinea pig skin as the membrane. They concluded that the passage of picrate ion through this membrane in the presence of DMSO was a passive diffusion process which adhered to Fick's first law of diffusion. It is demonstrated by diffusion and isotope studies that the absolute rate constant for the penetration of DMSO was approximately 100 times greater than that for the picrate ion. Thus, the two substances were transferred through the skin independently of each other. The exact mechanisms involved in the membrane penetrant action of DMSO have yet to be elucidated.
Studies on membrane penetration and carrier effect have been carrier effect have been carried out in agriculture, basic biology, animals, and man. In field tests with severely diseased fruit, Keil55 demonstrated that oxytetracycline satisfactorily controlled bacterial spot in peaches. Control was significantly enhanced by adding DMSO to the antibiotic spray. DMSO was applied to 0.25 and 0.5% with 66 ppm of oxytetracycline. This application gave control of the disease similar to that produced alone by 132 ppm of oxytetracycline and suggested the possibility of diluting the high-priced antibiotic with relatively inexpensive DMSO. There is no good evidence in animals that 0.5% DMSO has significant carrier effects. It could well be that Keil's results were attributable to a carrier effect, but the possibility should always be considered that when DMSO is combined with another substance a new compound results which can then exert a greater or lesser influence on a given process.
Leonard63 studied different concentrations of several water-soluable iron sources applied as foliage sprays to orange and grapefruit trees whose leaves showed visible signs of iron deficiency. The application of iron in DMSO as a spray was followed by a rapid and extensive greening of the leaves, with a higher concentration of chlorophyll.
Amstey and Parkman2 evaluated the influence of DMSO on the infectivity of viral nucleic acid, an indication of its transmembrane transport. It was found that DMSO enhanced polio RNA infectivity in kidney cells from monkeys. Enhancement occurred with all DMSO concentrations from 5 to 80% and was optimal at 40% DMSO, with a 20-minute absorption period at room temperature. A significant percentage of nucleic acid infection was absorbed within the first 2 minutes.
Cochran and his associates14 concluded that concentrations of DMSO below 20% did no influence the infectivity of tobacco mosaic virus (TMV) or the viral RNA. With concentrations between 20 and 60% the infectivity of TMV and TMV RNA varied inversely with the DMSO concentration.
Nadel and co-workers72 suggested that DMSO enhanced the penetration of the infectious agent in experimental leukemia of gunea pigs. Previously Schreck et al.97 had demonstrated that DMSO was more toxic in vitro to lymphocytic leukemia than to lymphocytes from normal patients.
Djan and Gunberg24 studied the percutaneous absorption of 17-estradiol dissolved in DMSO in the immature female rat. These steroids were given in aqueous solutions subcutaneously or were applied topically in DMSO. Vaginal and uterine weight increases resulting from estrogen in DMSO administered topically were comparable to results obtained in animals in which the drugs were administered in pure form subcutaneously.
Smith102 reported that a mixture of DMSO and diptheria toxoid applied frequently to the backs of rabbits causes a reduction of the inflammation produced by the Shick test, indicating that a partial immunity of diphtheria has been produced.
Finney and his associates29 studied the influence of DMSO and DMSO-hydrogen peroxide on the pig myocardium after acute coronary ligation with subsequent myocardial infaction. The addition of DMSO to a hydrogen peroxide perfusion system fascilitated the difffusion of oxygen into the ischemic myocardium.
Maddock et al.66 designed experiments to determine the usefulness of DMSO as a carrier for antitumor agents. The agents were dissoved in 85-100% concentrations of DMSO. One of the tumors studied was the L1210 leukemia. Survival time without treatment was appoximately 8 days. The standard method of employing Cytoxan intraperitoneally produced a survival time of 15.5 days. When Cytoxan was applied topically in water, the survival time was 12.6 days, and topical Cytoxan dissolved in DMSO resulted in survival time of 15.3 days.
Spruance recently studied DMSO as a vehicle for topical antiviral agents, concluding that the penetration of acyclovir (ACV) through guinea pigs skin in vitro was markedly greater with DMSO than when ployethylene glycol (PEG) was the vehicle. When 5% ACV in DMSO was compared with 5% ACV in PEG in the treatmental herpes infection in the guinea pig, ACV DMSO was more effective.103
The possibility of altering the blood-brain diffusion barrrier with DMSO needs additional exploration. Brink and Stein10 employed [14C]pemoline dissolved in DMSO and injected intraperitoneally into rats. It was found in larger amounts in the brain than was a similar dose given in 0.3% tragacanth suspension. The authors postulated that DMSO resulted in a partial breakdown of the blood-brain diffusion barrier in vitro.
There is conflicting evidence as to whether dimethyl sulfoxide can reversibly open the blood-brain barrier and augment brain uptake of water-soluable compounds, including anticancer agents. To investigate this, 125[-Human serum albumin, horse-radish peroxidase, or the anticancer drug melphalan was administered iv to rats or mice, either alone or in combination with DMSO. DMSO administration did not significantly increase the brain uptake of any of the compounds as compared to control uptakes. These results do not support prior reports that DMSO increases the permeability of water-soluable agents across the blood-brain barrier.43
Maibach and Feldmann67 studied the percutaneous penetration of hydrocortisone and testosterone in DMSO. The authors concluded that there was a threefold increase in dermal penetration by these steroids when they were dissolved in DMSO.
Sulzberger and his co-workers107 evaluated the penetration of DMSO into human skin employing methylene blue, iodine, and iron dyes as visual tracers. Biopsies showed that the stratum corneum was completely stained with each tracer applied to the skin surface in DMSO. There was little or no staining below this layer. The authors concluded that DMSO carried substances rapidly and deeply into the horny layer and suggested the usefulness of DMSO as a vehicle for therapeutic agents in inflammatory dermatoses and superficial skin infections such as pyodermas.
Perliman and Wolfe76 demonstrated that allergens of low molecular weight such as penicillin G potassium, mixed in 90% DMSO, were readily carried through intact human skin. Allergens having molecular weights of 3000 or more dissolved in DMSO did not penetrate human skin in these studies. On the other hand, Smith and Hegre101 had previously recorded that antibodies to bovine serum albumin developed when a mixture of DMSO and bovine serum albumin was applied to the skin of rabbits.
Turco and Canada112 have studied the influence of DMSO on lowering electrical skin resistance in man, In combination with 9% sodium chloride in distilled water, 40% DMSO decreased resistance by 100%. It was postulated that DMSO in combination with electrolytes reduced the electrical resistance of the skin by facilitating the absorption of these electrolytes while it was itself being absorbed.
DMSO in some instances will carry substances such as hydrocortisone or hexachlorophene into the deeper layers of the stratum corneum, producing a reservoir.104 This reservoir remains for 16 days and resists depletion by washing of the skin surface with soap, water, or alcohol.105
C. Effect on Collagen
Mayer and associates69 compared the effects of DMSO, DMSO with cortisone acetate, cortisone acetate alone, and saline solutions on the incidence of adhesions following vigorous serosal abrasions of the terminal ileum of Wistar rats. Their technique had developed adhesions in 100% of control animals in 35 days. The treatments were administered daily as postoperative intraperitoneal injections for 35 days. The incidence of adhesions in different groups was DMSO alone: 20%, DMSO-cortisone: 80%, cortisone alone: 100%, saline solution: 100%.
It has been observed in serial biopsy specimens taken from the skin of patients with scleroderma that there is a dissolution of collagen, the elastic fibers remaining intact.93 Gries et al.44 studied rabbit skin before and after 24 hour in vitro exposure to 100% DMSO. After immersion in DMSO the collagen fraction extractable with neutral salt solution was significantly decreased. The authors recorded that topical DMSO in man exerted a significant effect on the pathological deposition of collagen in human postirradiation subcutaneous fibrosis but did not appear to change the equilibrium of collagen metabolism in normal tissue. Urinary hydroxyproline levels are increased in scleroderma patients treated with topical DMSO.93 Keloids biopsied in man before and after DMSO therapy show histological improvement toward normalcy.28
D. Anti-Inflammation
Berliner and Ruhmann7 found that DMSO inhibited fibroblastic proliferation in vitro. Ashley et al.3 reported that DMSO was ineffective in edema following thermal burns of the limbs of rabbits. Formanek and Kovak31 showed that topically applied DMSO inhibited traumatic edema induced by intrapedal injection of autologous blood in the leg of a rat.
DMSO showed no anti-inflammatory effect when studied in experimental effect when studied in experimental inflammation induced in the rabbit eye by mustard oil in the rat ear by croton oil.79
Gorog and Kovacs40 demonstrated that DMSO exerted minimal anti-inflammation effects on edema induced by carrageenan. These authors also studied the anti-inflammatory potential of DMSO in adjuvant-induced polyarthritis of rats. Topical DMSO showed potent anti-inflammatory properties in this model. Gorog and Kovacs41 have also studied the anti-inflammatory activity of topical DMSO, in contact dermatitis, allergic eczema, and calcification of the skin of thr rat, using 70% DMSO to treat the experimental inflammation. All these reactions were significantly inhibited.
The study of Weissmann et al.114 deserves mention in discussing the anti-inflammatory effects of DMSO. Lysosomes can be stabilized against a variety of injurious agents by cortisone, and the concentration of the agent necessary to stabilize lysosomes is reduced 10- to 1000-fold by DMSO. The possibility was suggested that DMSO might render steroids more available to their targets within tissues (membranes of cells or their organelles).
Suckert106 has demonstrated anti-inflammatory effects with intra-articular DMSO in rabbits following the creation of experimental [croton oil] arthritis.
E. Nerve Blockade (Analgesia)
Immersion of the sciatic nerve in 6% DMSO decreases the conduction velocity by 40%. This effect is totally reversed by washing the nerve in a buffer for 1 hour.89 Shealy99 studied peripheral small fiber after-discharge in the cat. Concentrations of 5-10% DMSO eliminated the activity of C fibers with 1 minute: activity of the fibers returned after the DMSO was washed away.
DMSO injected subcutaneously in 10% concentration into cats produced a total loss of the central pain response. Two milliliters of 50% DMSO injected into the cerebrospinal fluid led to total anesthesia of the animal for 30 minutes. Complete recovery of the animal occurred without apparent ill effect.100
Haigler concluded that DMSO is a drug that produced analgesia by acting both locally and systemically. The analgesia appeared to be unrelated to that produced by morphine although the two appear to be a comparable magnitude. DMSO had a longer duration of action than morphine, 6 hr vs 2 hr, respectively.45
F. Bacteriostasis
DMSO exerts a marked inhibitory effect on a wide range of bacteria and fungi including at least one parasite, at concentrations (30-50%) likely to be encountered in antimicrobial testing programs in industry.6
DMSO at 80% concentration inactivated viruses tested by Chan and Gadenbusch. These viruses included four RNA viruses, influenza A virus, influenza A-2 virus, Newcastle disease virus, Semliki Forest virus, and DNA viruses.12
Seibert and co-worker98 studied the highly pleomorphic bacteria regularly isolated from human tumors and leukemic blood. DMSO in 12.5-25% concentration caused complete inhibition of growth in vitro of 27 such organisms without affecting the intact blood cells.
Among the intriguing possibilities for the use of DMSO is its ability to alter bacterial resistance. Pottz and associates78 presented evidence that the tubercle bacillus, resistant to 2000Ýg of treptomycin or isoniazide, became sensitive to 10Ýg of either drug after pretreatment with 0.5-5% DMSO.
Kamiya et al.54 found that 5% DMSO restored and increased the sensitivity of antibiotic-resistant strains of bacteria. In particular, the sensitivity of all four strains of Pseudomonas to colistin was restored when the medium contained 5% DMSO. The authors recorded that antibiotics not effective against certain bacteria, such as penicillin to E. coli, showed growth inhibitory effects when the medium contained DMSO.
Ghajar and Harmon35 studied the influence of DMSO on the permeability of Staphylococcus aureau, demonstrating that DMSO increased the oxygen uptake but reduced the rate of glycine transport. They could not define the exact mechanism by which DMSO produced its bacteriostatic effect.
Gillchriest and Nelson37 have suggested that bacteriostasis from DMSO occurs due to a loss of RNA conformational structure required for protein synthesis.
G. Diuresis
Formanek and Suckert32 studied the diuretic effects of DMSO administered topically to rats five times daily in a dosage of 0.5 ml of 90% DMSO per animal. The urine volume was increased 10-fold, and with the increase in urine volume, there was an increase in sodium and potassium excretion.
H. Enhancement or Reduction of Concomitant Drug Action
Rosen and associates84 employed aqueous DMSO to alter the LD50 in rats and mice when oral quaternary ammonium salts were used as test compounds. In rats, the toxicity of pentolinium tartrate and hexamethonium bitartrate was increased by DMSO, while the toxicity of hexamethonium iodide was decreased.
Male68 has shown that DMSO concentrations of upward to 10% lead to a decided increase in the effectiveness of griseofulvin.
Melville and co-workers70 have studied the potentiating action of DMSO on cardioactive glycosides in cats, including the fact that DMSO potentiates the action of digitoxin. This effect, however, does not appear to involve any change in the rate of uptake (influx) or the rate of loss (efflux) of glycosides in the heart.
I. Cholinesterase
Sams et al.90 studied the effects of DMSO on skeletal, smooth, and cardiac muscle, employing concentrations of 0.6-6%. DMSO strikingly depressed the response of the diaphragm to both direct (muscle) and indirect (nerve) electrical stimulation, and caused spontaneous skeletal muscle fasciculations. DMSO increased the response of the smooth muscle of the stomach to both muscle and nerve stimulations. The vagal threshold was lowered 50% by 6% DMSO. Cholinesterase inhibition could reasonably explain fasciculations of skeletal muscle, increased tone of smooth muscle, and the lower vagal threshold observed in these experiments. In vitro assays show that 0.8-8% DMSO inhibits bovine erythrocyte cholinesterase 16-18%.
J. Nonspecific Enhancement of Resistance
In a study of antigen-antibody reactions, Reattig81 showed that DMSO did not disturb the immune response. In fact, the oral administration of DMSO to mice for 10 days prior to an oral infection with murine typhus produced a leukocytosis and enhanced resistance to the bacterial infection.
K. Vasodilation
Adamson and his co-workers1 applied DMSO to a 3-1 pedicle flap raised on the back of rats. The anticipated slough was decreased by 70%. The authors suggested that the primary action of DMSO on pedicle flap circulation was to provoke a histamine-like reponse. Roth87 has also evaluated the effects of DMSO on pedicle flap blood flow and survival, concluding that DMSO does indeed increase pedicle flap survival, but postulating that this increase takes place by some mechanism other than augmentation of perfusion. Kligman56, 57 had previously demonstrated that DMSO possesses potent histamine-liberating properties.
Leon62 has studied the influence of DMSO on experimental myocardial necrosis. DMSO therapy effected a distinct modification with less myocardial fiber necrosis and reduced residual myocardial fibrosis. The author reported that neither myocardial rupture nor aneurysm occured in the group treated with DMSO.
L. Muscle Relaxation
DMSO applied topically to the skin of patients produces electromyographic evidence of muscle relaxation 1 hour after application.8
M. Antagonism to Platelet Aggregation
Deutsch23 has presented experimental data showing that 5% DMSO lessons the adhesiveness of blood platelets in vitro. Gorog39 has shown that DMSO is a good antagonist to platelet aggregation as well as thrombus formation in vivo. Gorog evaluated this in the hamster cheek pouch model.
N. Enhancement of Cell Differentiation and Function
It has been shown that dimethyl sulfoxide induces differentiation and function of leukemic cells of mouse 11, 33, 46, 65, 92, 115, rat,58 and human.9, 15, 16, 34, 109 DMSO was also found to stimulate albumin production in malignantly transformed hepatocytes of mouse and rat49 and to affect the membrane-associated antigen, enzymes, and glycoproteins in human rectal adenocarcinoma cells.111 Hydrocortisone-induced keratinization of chick embryo cells74 and adriamcycin-induced necrosis of rat skin108 were inhibited by DMSO.
Furthermore, modification by DMSO of the function of normal cells has been reported. DMSO stimulates cyclic AMP accumulation and lipolysis and decreases insulin-stimulated glucose oxidation in free white fat cells of [the] rat. It also enhances heme synthesis in quail embryo yolk sac cells.110
Leukemic blasts can be induced by external chemical agents to mature to neutrophils, monocytes, or RBCs. The phenotype of leukemic cells thus results from both internal genetic aberrations and the response of leukemic cells to their external environment. When human myeloid leukemia cells are exposed in vitro to a variety of agents (e.g.vitamin A or dimenthyl sulfoxide) the blasts lose their proliferative potential, the expression of oncogene products is sharply decreased, and after 5 days the leukemic cells become morphologically mature and functional neutrophils. Some patients with myeloid leukemias have responded to therapy designed to induce maturation in vivo. The induced maturation of leukemic cells is a new therapeutic tactic-alternative to cytotoxic drug therapy-wherein leukemic cells are destroyed by transforming them into neutrophils.86
O. Influence on Serum Cholesterol in Experimental Hypercholesterolemia
Rabbits given a high cholesterol diet with 1% DMSO showed one-half as much hypercholesterolemia as control animals.48
P. Radioprotective and Cryoprotective Actions
M.J. Ashwood-Smith has written a comprehensive review of these actions.4
Q. Protection against Ischemic Injury
De la Torre has advanced a scheme based on both investigated and theoretical actions of DMSO on the biochemical events generated after an ischemic injury. He previously proposed this hypothetical model to help conceptualize how DMSO, or similar drugs, mights affect the pathochemical balance that results in lack of tissue perfusion following trauma.19
The biochemical and vascular responses to injury appear to have a cause and effect relationship that can be integrated in terms of substances that either increase or decrease blood flow. The substance's effect can be physical, i.e. reduce or increase the vessel lumen obstruction, or chemical, i.e. reduce or increase the vessel lumen diameter (vasoconstriction/vasodilation).
Platelets, for example, can induce both conditions. Obstruction of the vessel lumen can result from platelet adhesion (platelet buildup in damaged vessel lining) or platelet aggregation. Platelet damage moreover can cause vasoconstriction or vasospasm by liberating vasoactive substances locally with the blood vessel or perivascularly, if penetrating damage to the vessel has occurred. There are two storage sites within platelets that contain most of these vasoactive substances. The alpha granules contain fibrinogen, while the dense bodies store ATP, ADP, serotonin, and calcium, which can be secreted by the platelet into the circulation by a canalicular system.5 Thromboxane A2 has also been shown to be manufactured in the microsomal fraction of animal and human platelets.73 All these vasoactive substances (with the exception of ATP) can cause significant reduction of blood flow by physical or chemical reactivity on the vasculature.
DMSO can antagonize a number of these vasoactive substances released by the platelets, which could consequently induce vasoconstriction, vasospasm, or obstruction of vessel lumen. For example, a study has shown that DMSO can inhibit ADP and thrombin-induced platelet aggregation in vitro.95 It may presumable do this by increasing the evels of cAMP (a strong platelet deaggregator) through inhibition of its degradative enzyme, phosphodiesterase.26, 51 DMSO is reported to deaggregate platelets in vivo following experimental cerebral ischemia.26, 51 This effect may be fundamental in view of the finding that cerebral ischemia produces transient platelet abnormalities that may promote microvascular aggregation formation and extend the area of ischemic injury.25
The biochemical picture is further complicated by the possible activity of DMSO on other vasoactive substances secreted by the platelets during injury or ischemia. For example, the release of calcium from cells from cells or platelets and its effect on arteriolar-wall muscle spasm may be antagonized by circulating DMSO.13, 88 Collagen-induced platelet release may also be blocked by DMSO.44, 94
The following effects of DMSO are likely to be involved in its ability to protect against ischemic injury.
DMSO and PGTX System
Little is known about the actions of DMSO on the prostanoids (PG/TX). Studies have reported that DMSO can increase the synthesis of PGE1, a moderate vasodilator.61. PGE1 can reduce platelet aggregation by increasing cAMP levels and also inhibit the calcium-induced release of noradrenalin in nerve terminals, an affect that may antagonize vasoconstriction and reduction of cerebral blood flow.53
DMSO, it will be recalled, also has a direct effect on cAMP. It increases cAMP presumably by inhibiting phosphodiesterase,113 although an indirect action on PGI2-induced elevation of platelet cAMP by DMSO should not be ruled out. Any process that increases platelet cAMP will exert strong platelet deaggregation.
It has also been reported that DMSO can block PFG2 receptors and reduce PFE2 synthesis.82 Both these compounds can cause moderate platelet aggregation and PFG2 is known to induce vasoconstriction.60 The effects of DMSO on thromboxane synthesis are unknown. It could, however, inhibit TXA2, biosynthesis in much the same way as hydralazine or dipyridamole42 since it shares a number of similar properties with these agents: specifically, their increase of cAMP levels.
DMSO and Cell Membrane Protection
The ability of DMSO to protect cell membrane integrity in various injury models is well documented.38, 64, 91, 114
Cell membrane preservation by DMSO might help explain its ability to improve cerebral and spinal cord blood flow after injury.18 DMSO could be preventing impairment of cerebrovascular endothelial surfaces where PGI2 is elaborated and where platelets can accumulate following injury. The effects of DMSO may be two-fold: reduction of platelet adhesion by collagen,44 and reduction of platelet adhesion by protecting the vascular endothelium and ensuring PGI2 release.
DMSO, Hydroxyl Radicals, and Calcium
Although many hormones, chemical transmitters, peptides, and numerous enzymes can be found in mammalian circulation at any given time, it is the hydrozyl radicals that have drawn attention by playing an important role in the pathogenesis of ischemia.21, 30 Free radicals can be elaborated by peroxidation of cellular membrane-bound lipids where oxygen delivery is not totally abolished, as in ischemia and hypoxia, or when oxygen is resupplied after an ischemic episode.83
One of the significant sites where hydroxyl radicals can form following ischemia is in mitochondria. DMSO is known to be an effective hydroxyl radical scavenger.4, 20, 75 Since it has been shown that DMSO can improve mitochondrial oxidative phosphorylation, it has been suggested that DMSO may act to neutralize the cytotoxic effects of hydroxyl radicals in mitochondria themselves.96 Oxidative phosphorylation is one of the primary biochemical activities to be negatively affected following ischemic injury. DMSO has also been reported to reduce ATPase activity in submitochondrial particles,17, 36 an effect that can lower oxygen utilization during cellular ischemia.
It has been proposed that DMSO may reduce the utilization of oxygen by an inhibiting effect on mitochondrial function. In one experiment the energy loss due to inhibition of oxidative activity after brain tissue was perfused with DMSO was compensated for by an increase in glycolysis.36
It seems probable that the neutralizing action of DMSO on hydroxyl radical damage following injury could diminish the negative outcome of ischemia. However the formation of hydroxyl radicals is dependent on time and oxygen availability, but the development of ischemia is immediate and its reversal may depend on more prevalent subsystems such as the PG/TX and platelet interactions. Maintaining the balance of these subsystems appears more critical in predisposing the outcome of cerebral ischemia.
Another interesting effect of DMSO is on calcium. When isolated rat hearts are perfused with calcium-free solution followed by reperfusion with a calcium-containing solution, a massive release of creatine kinase (indicating cardiac injury) is observed. This creatine kinase level increase is accompanied by electrocardiographic (EKG) changes and ultrastructural cell damage.50 DMSO has been reported to significantly reduce the release of creatine kinase and prevent EKG and ultrastructural changes if it is present during reperfusion of the isolated rat heart with a calcium-containing solution.88 Moreover, examination of the heart tissue by electron microscopy showed that DMSO-treated preparations lacked the mitochondrial swelling and contraction band formation otherwise induced by the reentry of calcium.88 These findings are supported by another investigation showing that DMSO can block calcium-induced degeneration of isolated myocardial cells.13 This protective effect by DMSO on myocardial tissue may be critical during ischemic myocardial infarction when evolutionary EKG changes, serum creates kinase levels are elevated, and myocardial necrosis can develop rapidly.
DMSO2 is not an effective cryoprotective agent; however, Herschler47 has recorded that DMSO (dimethyl sulfone) is a natural source of biotransformable sulfur in plants and lower animals. Jacob and Herschler have reported a number of unique properties possessed by DMSO.52 Since DMSO is oxidized to DMSO2 in vivo, scientists should include DMSO as a control in basic biologic studies on DMSO in plants and animals.
Footnotes
(a) Although the abbreviation "Me2SO" has been recommended for chemists by the IUPAC, the abbreviation for dimethyl sulfoxide most familiar to those concerned with its medicinal uses is "DMSO." Consequently, this generic pharmacological name for dimethyl sulfoxide will be employed throughout this paper.
(b) Supported in part by a grant from The Ronald J. Purer Foundation. Presented at the Symposium Biological Effects of Cryoprotective Agents at the Cryobiology Meeting, June 1985, Madison, Wis.
(c) Stanley W. Jacob, MD, Gerlinger Associate Professor of Surgery and Surgical Research.
References
1. Adamson, J. E., Crawford, H. H., and Horton,
C.E. The action of dimenthyl sulfoxide on the experimental
pedicle flap. Surg. Forum. 17:491-492 (1966).
2. Amstey, M.S., and Parkman, P.D. Enhancement of
polio RNA infectivity by dimenthyl sulfoxie. Proc. Soc. Exp.
Biol. Med. 123:438-442 (1966)
3. Ashley, F.L., Johnson, A.N., McConnell, D.V.,
Galloway, D.V., Machida, R.C., and Sterling, H.E. Dimethyl
Sulfoxide and burn edema. Ann. N.Y. Acad. Sci. 141: 463-464
(1967).
4. Ashwood-Smith, M.J. Current concepts concerning
radioprotective and cryroprotetive properties or dimethyl
sulfoxide in cellular systems. Ann. N.Y. Acad. Sci. 141: 41-62
(1967).
5. Baldini, M.G., and Myers, T.J. One more variety
of storage pool disease. J. Amer Med. Assoc. 244: 173-175
(1980).
6. Basch, H., and Gadebusch, H.H. In vitro
antimicrobial activity of dimethyl sulfoxide. Appl. Microbiol.
16: 1953-1954 (1968).
7. Berliner,D.L., and Ruhmann, A.G. The influence
of dimethyl sulfoxide on fibroblastic proliferation. Ann. N.Y.
Acad. Sci. 141: 159-164 (1964).
8. Birkmayer, W., Danielczyk, W., and Werner, H.
DMSO bei spondylogenen neuropathien. In "DMSO Symposium, Vienna,
1966" (G. Laudahn and K. Gertich, Eds.) pp. 134-136 Saladruck,
Berlin (1966).
9. Bonder, R.W., Siegel, M.I., McConnell, R.T., and
Cuatrecasesk P. The appearance of phospholipase and
cyclo-oxygenase activities in the human promyelocytic leukemia
cell line HL-60 during dimethyl sulfoxide-induced
differentiation. Biochem. Biophys. Res Commun. 98: 614-620
(1981).
10. Brink, J.J., and Stein. D.G. Pemoline levels in
brain-enhancement by dimethyl sulfoxide. Science (Washington,
D.C.) 158: 1479-1480 (1967).
11. Brown, A.E., Schwartz, E.L., Dreyer, R.N., and
Satrorelli, A.C. Synthesis of sialoglycoconjugates during
dimethyl sulfoxide-induced erythrodifferentiation of Friend
Leukemia cells. Biochem. Biophys. Acta 717: 217-225 (1982).
12. Chan, J.C., and Gadebusch, H.H. Virucidal properties
of dimethyl sulfoxide. Appl. Microbiol. 16: 1625-1626 (1968).
13. Clark, M.G., Gannon, B.J., Bodkin, N., Patten, G.S.,
and Berry, M.N. An improved procedure for high-yield preparation
of intact beating heart cells from adult rat: Biochemical and
moronologic study. J. Mol. Cell. Cariol 10: 1101-1121 (1978).
14. Cohran, G.W., Dhaliwal, A.S., Forghani, B. Chideste,
J.L., Dhaliwal, G.K., and Lambron, C.R. Action of dimethyl
sulfoxide on tobacco mosaic virus. Phytopathology 57, 97 (1967).
(abstract).
15. Collins, S.J., Ruscetti, F.W., Gallagher, R.E., and
Gallo, R.C. Terminal differentiation of human promyelocytic
leukemia cells induced in dimethyl sulfoxide and other polar
compounds. Proc. Natl. Acad. Sci. USA 75: 2458-2462 (1978).
16. Collins, S.J., Ruscetti, F.W., Gallagher, R.E., and
Gallo, R.C. Normal functional characteristics of cultured human
promyelocytic leukemia cells (HL-60) after induction of
differentation by dimethyl sulfoxide. J. Exp. Med. 149: 969-974
(1979).
17. Conover, T.E. Influence of nonionic organic solutes
on various reactions of energy conservation and utilization.
Ann. N.Y. Acad. Sci. 243: 24-37 (1975).
18. De la Torre, J.C. Spinal Cord Injury: Review of basic
and applied research. Spine 6. 315-335 (1981).
19. De la Torre, J.C., Surgeon, J. W., Hill, P.K., and
Khan, T. DMSO in the treatment of brain infrction: Basic
considerations. In "Arterial Air Embolism and Acute Stroke:
Report No. 11/15/77" (J.M. Hallenbeck and L. Greenbaum, Eds.)
pp. 138-161. Undersea Medical Society, Bethesda, Md. (1977).
20. Del Maestro, R., Thaw, H.H., Bjork, J., Planker, M.,
and Arfors, K.E. Free radicals as mediators of tissue injury.
Acta. Physiol. Scand. Suppl. 492: 91-119 (1980).
21. Demonpoulos, H.B., Flamm, E., Pietronigro, D., and
Seligman, M.L. The free radical pathology and the
microcirculation in the major central nervous system disorders.
Acta. Physiol. Scand. Suppl. 492: 91-119 (1980).
22. Denko, C.W., Goodman, R.M., Miller, R., and Donovan,
T. Distribution of dimthyl sulfoxide-35S in the rat. Ann. N.Y.
Acad. Sci. 141: 77084 (1967).
23. Deutsch, E., Beeinflussung der Blutgerinnung durch
DMSO und Kombinationen mit Heparin, In "DMSO Symposium, Vienna,
1966" (G. Laudahn and K. Gertich, Eds.) pp.144-149. Saladruck,
Berlin. 1966.
24. Djan, T.I., and Gunber, D.L. Percutaneous absorption
of two steriods dissoved in dimethyl surlfoxide in the immature
female rat. Ann. N.Y. Acad. Sci. 141: 406-413 (1967).
25. Dougherty, J.H., Levy, D.E., and Weksler, B.B.
Experimental cerebral ischemia produces platelet aggregates.
Neurology 29: 1460-1465 (1979).
26. Dujovny, M., Rozano, R., Kossovsky, N., Diaz, F.G.,
and Segal, R. Antiplatelet effect of dimethyl sulfoxide.
barbiturates and methyl prednisoione. Ann. N.Y. Acad. Sci.
441:234-244 (1983).
27. Elfbaum, S.G., and Laden K. Effect of dimethyl
sulfoxide on percutaneous absorption--a mechanistic study. J.
Soc. Cosmet. Chem. 19, 841 (1968) (Abstract).
28. Engle, M.F. Indications and contraindications for the
use of DMSO in clinical dermatology. Ann. N.Y. Acad. Sci. 141:
638-645 (1967).
29. Finney, J.W., Urschel, H.C., Balla, G.A., Race, G.J.,
Jay, B.E., Pingree, H.P., Dorman, H.L., and Mallams, J.T.
Protection of the ischemic heart with DMSO alone or DMSO with
hydrogen peroxide. Ann. N.Y. Acad. Sci. 141: 231-241 (1967).
30. Flamm, E.S., Demonpoulos, H., Seligman, M., and
Ransohoff, J. Free radicals in cerebral ischemica. Stroke 9:
445-447 (1978).
31. Formanek, K., and Kovac, W. DMSO bei experimentellen
Rattenpfotenodemen. In "DMSO Symposium, Vienna, 1966" (G.
Laudahn and K. Gertich, Eds.). pp.18-24. Saladruck. Berlin.
1966.
32. Formanek, K., and Suckert, R. Diuretische Wirkung von
DMSO. In "DMSO Symposium, Vienna, 1966" (G. Laudahn and K.
Gertich, Eds.). pp.21-24. Saladruck. Berlin. 1966.
33. Friend, C., Scher, W., Holland, J.G., and Sato. T.
Hemoglobin synthesis in murine virus-induced leukemic cells in
vitro: Stimulation of erythroid differentiation by dimethyl
sulfoxide. Proc. Natl. Acad. Sci. USA 68: 378-382.(1971).
34. Gahmberg, C.G., Nilsson, K., and Anderson, L.C.
Specific changes in the surface glycoprotein pattern of human
promyelocytic leukemic cell line HL-60 during morphologic and
functional differentiation. Proc. Natl. Acad. Sci. USA 76:
4087-4091. (1979).
35. Ghajar, B.M., and Harmon, S.A. Effect of dimethyl
sulfoxide (DMSO) on permeability of Staphylococcus aurens.
Biochem. Biophys. Res. Commun. 32: 940-944 (1968).
36. Ghosh, A.K., Ito, T., Ghosh, S., and Sloviter, H.A.
Effects of dimethyl sulfoxide on metabolism of isolated perfused
rat brain. Biochem Pharmacol. 25: 1115-1117 (1976).
37. Gillchriest, W.C., and Nelson, P.L. Protein synthesis
in bacterial and mammalian cells. Biophys. J. 9: A-133 (1969).
38. Gollan, F. Effect of DMSO and THAM on ionizing
radiation in mice. Ann. N.Y. Acad. Sci. 141: 63-64 (1967).
39. Gorog, P. Personal communications. May 10, 1969.
40. Gorog, P., and Kovacs, I.B. Effect on dimethyl
sulfoxide (DMSO) on various experimental inflammations. Curr.
Ther. Res. 10: 486-492 (1968).
41. Gorog, P., and Kovaces, I.B. Effect of dimethyl
sulfoxide (DMSO) on various experimental cutaneous ractions.
Pharmacology 67: in press.
42. Greenwald, J.E., Wong, K.E., Alexander, M., and
Bianchine, J.R. In vitro inhibition of thromboxane biosynthesis
by hydralazine. Adv. Prostaglandin Thromboxane Res. 6: 293-295
(1980).
43. Greig, N.H., Sweeney, D.J., and Rapoport, S. I.
Inability of dimethyl sulfoxide to increase brain uptake of
water-soluble compounds: Implications to chemotherapy for brain
tumors. Cancer Treat. Rep. 69: 305-12 (1985).
44. Gries, G., Bublitz, G., and Lindner. J. The effect of
dimethyl sulfoxide on the components of connective tissue
(Clinical and experimental investigations). Ann. N.Y. Acad. Sci.
141: 630-637 (1967).
45. Haigler, H.J. Comparison of the analgesic effects of
dimethyl sulfoxide and morphine. Ann. N.Y. Acad. Sci. 411: 19-27
(1983).
46. Hannania, N., Shaool, D., Poncy, C., and Harel, J.
New gene expression in dimethyl sulfoxide treated Friend
erytholeukemia cells. Exp. Cell Res. 130: 119-126 (1980).
47. Herschler, R.J. Unpublished data.
48. Herzmann, E. Studies of the effect of dimethyl
sulfoxide on experimental hypercholesterolemia in young cocks.
Acta. Biol. Med. Ger. 20: 483-487 (1968).
49. Higgins, P.J., and Borentreund, E. Enhanced albumin
production by malignantly transformed hepatocytes during in
vitro exposure to dimethyl sulfoxide. Biochum. Biophys. Acta.
610: 174-180 (1980).
50. Holland, C.E., and Olson, R.E. Prevention by
hypothermia of paradoxical calcium necrosis in cardiac muscle.
J. Mol. Cell Cardiol. 7: 917-928 (1975).
51. Holtz, G.C., and Davis, R.B. Inhibition of human
platelet aggregation in dimethyl sulfoxide, dimethyl acetamidine
and sodium glycerophosphate. Proc. Soc. Exp. Biol. Med. 141:
244-248 (1974).
52. Jacob, S.W., and Herschler, R. Introductory remarks:
Dimethyl sulfoxide after twenty years. Ann. N.Y. Acad. Sci. 441:
xiii-xvii (1983).
53. Johnson, M. and Ramwell, P.W. Implications of
prostaglandins in hematology. In "Prostaglandins and Cyclic AMP"
(R.H. Kahn and W.E.M. Lands, Eds.) pp. 275-304. Academic Press,
New York, (1974).
54. Kamiya, S., Wakao., T., and Nishioka, K. Studies on
improvement of eye drops. Bacteriological consideration of DMSO.
Jpn. J. Clin. Opthalmol. Rinsho Gank. 20: 143-152 (1966).
55. Keil, H. L. Enhanced bacterial sport control on peach
when dimethyl sulfoxide is combined with sprays of
oxytetracycline. Ann. N.Y. Acad. Sci. 141: 131-138 (1967).
56. Kligman, A.M. Topical pharacology and toxicology or
dimethyl sulfoxide (DMSO). Part 1. J. Amer. Med. Assoc. 193:
796-804 (1965).
57. Kligman. A.M. Topical pharmacology and toxicology of
dimethyl sulfoxide (DMSO). Part 2. J. Amer. Med. Assoc. 193:
923-928 (1965).
58. Kluge, N., Ostertag, W., Sugiyama, D., Arndt-Jovin,
D., Steinheider, G., Furusawa, M., and Dube, S. Dimethyl
sulfoxide-induced differentiation and hemoglobin synthesis in
tissue culture of rat erythroleukemia cells transformed by
7.12-dimethylbenz(a)anthracene. Proc. Natl. Acad. Sci. 73:
1237-1240 (1976).
59. Kolb, K.H., Janicke, G., Kramer, M., Schulze, P.E.,
and Raspe, G. Absorption, distribution and elimination of
labeled dimethyl sulfoxide in man and animals. Ann. N.Y. Acad.
Sci. 141: 85095 (1967).
60. Lefer, A.M. Role of the prostaglandin-thromboxane
system in vascular homeostasis during shock. Circ. Shock 6:
297-303. (1979).
61. LeHann, T.R., and Horita, A. Effects of dimethyl
sulfoxide (DMSO) on prostaglandin synthetase. Proc. West
Pharacol. Soc. 18: 81-82 (1975).
62. Leon, A. Personal communication. June 5, 1969.
63. Leonard, C.D. Use of dimethyl sulfoxide as a carrier
for iron in nutritional foliar sprays applied to citrus. Ann.
N.Y. Acad. Sci. 141: 148-158. (1967).
64. Lim, R., and Mullan, S. Enhancement of resistance of
glial cells by dimethyl sulfoxide against sonic disruption. Ann.
N.Y. Sci. 243: 358-361 (1975).
65. Lin, C.S. and Lin, M.C. Appearance of late-adrenergic
response of adenylate cyclase during the induction of
differentiation in cell cultures. Exp. Cell. Res. 112: 339-402.
(1979).
66. Maddock, C.L., Green, M.N., and Brown, B.L. Topical
administration of anti-tumor agents to locally implanted
neoplasma. Proc. Amer. A. Cancer Res. 7. 46. (1966) (abstract).
67. Maibach, H. I., and Feldmann, R. J. The effect on
DMSO of percutaneous penetration of hydrocortisone and
testosterone in man. Ann. N.Y. Acad. Sci. 141: 423-427 (1967).
68. Male, O. Enhancement of the antimycetic effectiveness
of Griseo-Fulvin by dimethyl sulfoxide in vitro. Arch. Klin.
Exp. Dermatol. 223: 63-76 (1968).
69. Mayer, J.H., III., Anido, H., Almond, C.H., and
Seaber., A. Dimethyl sulfoxide in prevention of intestinal
adhesions. Arch. Surg. 91: 920-923. (1965).
70. Melville, K.I., Klingner, B., and Shister, H.E.
Effects of dimethyl sulfoxide (DMSO) on cardiovascular responses
to Quabain. Proscillaridin and Digitoxin. Arch. Intern.
Pharmacodyn.174: 277-293. (1968).
71. Munoz, L.G., Rozario, R.A., Dujovny, M., and Stroth,
D. Antiplatelet properties of DMSO and barbiturates in
microvessels with scanning electron microscopy. J. Neurosurg.
52: 450 (1980) (Abstract).
72. Nadel, E.M., Nobel, J.G., Jr., and Burstein, S.
Observations on an effect of ACTH. dexamethasone. and dimethyl
sulfoxide (DMSO) on the "out of strain" transplantation and
lethality of strain 2 guinea pig leukemia LSC NB to strain 13
and Hartly animals. Cryobiology 5: 254-261 (1969).
73. Needleman, P., Moncade, S., Bunting, S., Vane, J.R.,
Hamber, M., and Samuelsson, B. Identification of any enzyme in
platelet microsomes which generates thromboxane A2 from
prostaglandin endoperoxides. Nature (London) 261: 558-560
(1976).
74. Obinata, A., Takata, K., Kawada, M., Hirano, H., and
Endo, H. Reversible inhibition by DMSO of hydrocortisone-induced
keratinization of chick embryonic skin. Exp. Cell Res. 138:
135-145 (1982).
75. Panganamala, R.V., Sharma, H.M., and Heikkila, R.E.
Role of hydroxyl radical scavengers, dimethyl sulfoxide,
alcohols, and methional in the inhibition of prostaglandin
synthesis. Prostaglandins 11: 599-607 (1976).
76. Perlman, F., and Wolfe, H.F. Dimethyl Sulfoxide as a
penetrant carrier of allergens through intact human skin. J.
Allergy 38: 299-307 (1966).
77. Phatek, N. Personal communication. June 5. (1969).
78. Pottz, G.E., Rampey, H., Jr, and Benjamin, A. Die
verwendung von DMSO zur Schellfarbung von Mykobakterien und
anderen Mikroorganismen in Abstrichen und Gewbeschnitten. In
"DMSO Symposium, Vienna. 1966." (G. Laudahand, K. Gertich,
Eds.). pp.40-43. Saladruck. Berlin. 1966.
79. Preziosi, P., and Scapgnini, U. Action of DMSO on
acut inflammatory reactions. Current Therap. Res. 8: 261-266.
(1966).
80. Rammier, D.H., and Zaffaroni, A. Biological
implications of DMSO based on a review of its chemical
properties. Ann. N.Y. Acad. Sci. 141: 13-23 (1967).
81. Raettig, H. Die Moglichkeiten des DMSO in der
experimentellen immunogie. In "DMSO Symposium, Vienna, 1966" (G.
Laudahn and K. Gertich, Eds.) pp. 51-56. Saladruck, Berlin,
(1966).
82. Rao, C.V. Differential effects of detergents and
dimethyl sulfoxide on membrane prostaglandin E, and F,
receptors. Life Sci. 20: 2013-2022 (1977).
83. Rehncrona, S., Siesjo, B.K., and Smith, D.S.
Reversible ischemia of the brain: Biochemical factors
influencing restitution. Acta. Physiol. Scand. Suppl. 492:
135-140 (1980).
84. Rosen, H., Blumenthal, A., Panacvich, R., and
McCallum, J. Dimethyl sulfoxide (DMSO) as a solvent in acute
toxicity determinations. Proc. Soc. Exp. Bio. Med. 120: 511-514
(1965).
85. Rosenblum, W.I., and El-Sabban, F. Dimethyl sulfoxide
and glycerol, nydroxyl radical scavengers, impair platelet
aggregation within and eliminate the accompanying vasodilation
of injured mouse pial arterioles. Stroke 13: 35-39 (1982).
86. Ross, D.W. Leukemic cell maturation. Arch. Pathol.
Lab. Med. 109: 309-313 (1985).
87. Roth, C.A. Effects of dimethyl sulfoxide on pedicle
flap flow and survival. J. Amer. Med. Women's Assoc. 23: 895-898
(1968).
88. Ruigrok, T.J.C., DeMoes, D., Slade, A.M., and Nayler,
W.G. The effect of dimethyl sulfoxide on the calcium paradox.
Amer. J. Pathol. 103: 390-403 (1981).
89. Sams, W.M., Jr. The effects of dimethyl sulfoxide on
nerve conduction. Ann. N.Y. Acad. Sci. 141: 242-247 (1967).
90. Sams, W.M., Carroll, N.V., and Crantz, P.L. Effects
of dimethyl sulfoxide on isolated innervated skeletal smooth and
cardiac muscle. Proc. Soc. Exp. Biol. Med. 122: 103-107 (1966).
91. Sandborn, E.B., Stephens, H., and Bendayan, M. The
influence of demethyl sulfoxide on cellular ultrastructure and
cytochemistry. Ann. N.Y. Acad. Sci. 243: 122-138 (1975).
92. Scher, B.M., Scher, W., Robinson, A., and Waxman, S.
DNA ligase and DNase activities in mouse erythroleukemic cells
during dimethyl sulfoxide-induced differentiation. Cancer Res.
42: 1300-1306 (1982).
93. Scherbel, A.L., McCormack, L.J., and Layle, J.K.
Further observations on the effect of dimethyl sulfoxide in
patients with generalized scleroderma (progressive systemic
sclerosis). Ann. N.Y. Sci. 141: 613-629 (1967).
94. Scherbel, A.L., McCormack, L.J., and Poppo, M.J.
Alterations of collagen in generalized scleroderma (progressive
systemic sclerosis) after treatment with dimethyl sulfoxide.
Cleveland Clin. Q. 32: 47-58 (1965).
95. Schiffer, C.A., Whitaker, C.l., Schmukler, M.,
Aisner, J., and Hibert, S.L. The effect of dimethyl sulfoxide on
in vitro platelet function. Thromb. Huemostasis 36: 221-229
(1976).
96. Schlafer, M., Kane, P.F., and Kirsch, M. Effects of
dimethyl sulfoxide on the globally ischemic heart: Possible
general relevance to hypothermic organ preservation.
Cryobiology. 19: 61-69 (1982).
97. Schreck, R., Elrod, L.M., and Batra, K.V. Cytocidal
effects of dimethyl sulfoxide on normal leukemic lymphocytes.
Ann. N.Y. Acad. Sci. 141: 202-213 (1967).
98. Seibert, F.B., Farrelly, F.K., and Shepherd, C.C.
DMSO and other combatants against bacteria isolated from
leukemia and cancer patients. Ann. N.Y. Acad. Sci. 141: 175-201
(1967).
99. Shealy, C.N. The physiological substrate of pain.
Headache 6: 101-108 (1966).
100. Shealy, C.N. Personal communication. June 5, 1969.
101. Smith, R.E., and Hegre, A.M.
102. Smith, R.E. The use of dimethyl sulfoxide in allergy
and immunology. E.E.N.T. Digest 30: 47-54 (1968).
103. Spruance, S.L., McKeough, M.B., and Cardinal, J.R.
Dimethyl Sulfoxide as a vehicle for topical antiviral
chemotherapy. Ann. N.Y. Acad. Sci. 411: 28-33 (1983).
104. Stoughton, R.B. Dimethyl sulfoxide (DMSO) induction
of a steroid reservoir in human skin. Arch. Dermatol. 91:
657-660 (1965).
105. Stoughton, R.B. Hexachlorophene deposidtion in human
stratum corneum. Enhancement by dimethylacetamide.
demethylsulfoxide. and methylethylether. Arch.Dermatol. 94:
646-648 (1966).
106. Suckert, V.R. Die Wirkung von Dimethylsulfozyd auf
die Crontronol-arthritis des Kaninchen-kniegelenkes.
Buchbesprechungen. 81: 157-158 (1969).
107. Sulzberger, M.B., Cortese, T.A., Jr., Fishman, L.,
Wiley, H.S., and Peyakovich, P.S. Some effects of DMSO on human
skin in vivo. Ann N.Y. Acad. Sci. 141: 437-450 (1967).
108. Svingen, B.A., Powis, G., Appel, P.L., and Scott, M.
Protection against adriamycininduced skin nectrosis in the rat
by dimethyl sulfoxide and alpha-tocopherol. Cancer Res. 41:
3395-3399 (1981).
109. Tarell, C., Ferrero, D., Gallo, E., Pagliardi, L.,
and Ruscetti, F.W. Induction of differentiation of HL-60 cells
by dimethyl sulfoxide: Evidence for a stochastic model not
linked to the cell division cycle. Cancer Res. 42: 445-449
(1982).
110. Tersawa, T., Miura, Y., and Masuda, R. The mechanism
of the action of DMSO on the heme synthesis of quail embryo yolk
sac cells. Exp. Cell Res. 133: 31-37 (1981).
111. Teso, D., Morita, A., Bella, A., Jr., Luu, P., and
Kim, Y.S. Differential effects of sodium butylate, dimethyl
sulfoxide and retinoic acid on membrane-associated antigen,
enzymes, and glycoproteins of human rectal adenocarcinoma cells.
Cancer Res. 42: 1052-1058 (1982).
112. Turco, S.J., and Canada, A.T. Effects of dimethyl
sulfoxide in lowering electrical skin resistance. Amer. J. Hosp.
Pharm. 26: 120-122 (1969).
113. Wieser, P.B., Zeiger, M.A., and Fain, J.N. Effects on
dimethyl sulfoxide on cyclic AMP accumulation, lipolysis and
glucose metabolism of fat cells. Biochem. Pharmacol. 26: 775-778
(1977).
114. Weissman, G., Sessa, G., and Bevans, V. Effect of
DMSO on the stabilization of lysosomes by cortisone and
chloroquine in vitro. Ann. N.Y. Acad. Sci. 141: 326-332 (1967).
115. Zwigeistein, G., Tapiero, H., Portoukalian J., and
Fourcade, A. Changes in phospholipid and fatty acid composition
in differntiated Friend leukemic cells. Biochem. Biophys. Res.
Commun. 98: 349-358 (1981).
Source: Received September 9, 1985. Accepted September 16, 1985 by the Academic Press, Inc. Printed 1985 (pp. 14-27). DMSO Organization wishes to thank the Academic Press, Inc., for allowing us to place this article on our World Wide Web site. Academic Press retains all copyright. To copy any portion of this article, please obtain permission from the publisher.
http://www.garynull.com/documents/Arthritis/DMSO_Treatments_in_Arthritis.htm
DMSO (Dimethylsulfoxide) Treatments in Arthritis
Jack Blount, M.D., Ronald M. Davis, M.D., Ray Evers, M.D., Stanley Wallace Jacob, M.D., Pat McGrady, Sr., Efrain Olszewer, M.D., Gus J. Prosch, Jr., M.D., Dr. Paul K. Pybus, Fuad C. Sabbag, M.D., Roger Wyburn-Mason, M.D., Ph.D., Alan Rory Zapata, M.D./Responsible editor/writer Anthony di Fabio.
... The 30 patients included in this study were regular patients in our clinic and were evaluated three times in order to see if it was possible to use the HLB test as a measuring method of FR, as well as DMSO as an optimum antioxidant. The results obtained are represented in Figure 1, where we find an initial average FR measuring 30.6% of the patients included, with an important and significant decrease of FR production after DMSO administration, obtaining lower levels with an average of 10.6%. That represents a 66% decrease in patients before beginning the DMSO therapy, and keeping the patients in monthly applications we obtained an average of 13.3% of FR synthesis. That represents 52% decrease than the patients had in the beginning, and 12% higher than patients after any DMSO infusion.
It is important to verify that the higher values were obtained in patients with RA, and the lowest in patients with OA.
This study was done by: Centro Internacional de Medicina Preventiva, Rua Compevas 211 Perdizes, Sao Paulo 1501. Brazil; Tel: (011) 623000.
References
1. Beary J. III. Ed. Manual of Rheumatology and outpatient
orthopedic disorders. A Little Brown 1981.
2. Decker J., Scott T. Eds. Perspectives in Rheumatology. Curr
Med Lit Ltd. 1984.
3. Wood D. and J. and JU., Pharmacology and Biochemical
considerations of DMSO. Annals of the NY Acad of Sci. 1982.
4. Gorog P, Kovacs I. Antiarthritic and antithrombotic effects
of topically applied DMSO. Annals of the NY Acad of Sci. 1982.
5. Bradford, Allen, Cullen: Oxidology. The R. Bradford Fdtn. Los
Altos, CA 1985.
6. Kuberampata T. et al. Effect of Adjuvant Arthritis on
collangenase and certain lysosomal enzymes in relation to the
catabolism of collagen. Agents Actions 10 78 1980.
7. Crossley M. et al. Biochemical and Pharamcological Studies on
Synovium Cartilage Interactions in Organic Culture. European
Journal of Rheumatology and Inflammation 5 15 1982.
8. Acta Univ. Ouluensis, Series A, 85(1979). Savulainen E.R.
Enzymes of Collagen biosynthesis in diseases of the liver and
connective tissues. Chyem Abst 9 1. 1729 lit. 1979.
9. Olszewer et al. Evaluacion clinica de pacientes con artrosis,
sometidos a tratamento com DMSO, mesoterapia y
mucopolisacaridios. Vol. 15, pp 14-17. Junio de 1991.
10. Olszewer E. A new approach to Rheumatoid diseases Townsend
Letter for Doctors. October 1991. Letter.
11. Olszewer E. Carter J. EDTA Chelation Therapy in Chronic
Degenerative Disease. Med. Hyp. 27, 41-49. 1988.
12. Olszewer E., Carter J., Sabbag F. A pilot double blind study
of Na-Mg EDTA in peripheral vascular disease, JNMA Vol. 82, N 3,
March 1990.
13. Pat McGrady, Sr., The Persecuted Drug: The Story of DMSO,
The Nutri-Books Corp., Box 5793, Denver, CO 80217, 1979.
References
1. Stein H. Jay. Medicina Interna. Tomo II. Slvat Editors.
1989.
2. Hughes R. Graham. Connective Tissue Diseases. Blackwell
Scientific Publ. 1977.
3. Jacobs S. Herschler R. Editors. Biological Actions of DMSO.
Annals of the New York Academy of Sciences. 1975.
4. Jacobs et al. American Journal of Surgery. 114:114. 1967.
5. Handler S. The Complete Guide to Anti-aging Nutrients. Simon
& Schuster. 1984.
6. Scherbel A. McCormack M. Alternation of collagen in
generalized scleroderma after treatment of DMSO. Cleveland
Clin.Quart. 32:47. 1965.
7. Gries B. Bublitz and lindner. The effects of DMSO on the
components of connective tissue. Ann. N.Y. Acad. Sci. 141:630.
1967.
8. Melzack R. Wall P. The Challenge of Pain. Penguin Books.
1988.
9. Harper H. Review of Physiological Chemistry. 17th Ed. Lange
Med. Publ. 1979.
10. McGrady P. The Persecuted Drug: The Story of DMSO. Doubleday
Co. 1973.
http://www.medical-library.net/content/view/270/41/
DMSO Therapy
The subject of DMSO therapy has its own web page on this site. I want to focus here on its use in cancer therapy. DMSO has many characteristics which make it a good adjunctive treatment for cancer. Recall from our previous discussion that DMSO is a super-solvent. It binds to water (which makes up around 65% of the body) better than water does. This gives DMSO the ability to penetrate every single cell of the body, so whatever its other effects may be, they will be spread systemically through the entire body. Whatever is administered with DMSO tends to bind with the DMSO and is carried to the inside of cells along with DMSO.
Animal studies show that DMSO, by itself, inhibits the growth of breast, colon and bladder cancer, as well as leukemia, in animals. The fact that this list is not longer probably reflects the fact that DMSO has not been studied in other cancers.
If cytotoxic drugs are given to fight a cancer, they are more effective when given with DMSO to escort them to the inside of cancer cells. DMSO also relieves the pain of cancer and, by being a free radical scavenger, reduces the side effects of radiation therapy.
But, it's the old story! As with most effective and affordable cancer therapies, it is not approved for that use by the FDA. This, despite the presence of more than 6,000 articles attesting to its safety and effectiveness and despite the fact that almost every civilized country approves of DMSO treatment for cancer except, you guessed it, the USA.
Nevertheless, some doctors do offer DMSO in the US. Because DMSO is approved for one rare bladder condition called "interstitial cystitis," it is possible for doctors to use it for any other purpose. The FDA's authority extends to the determination of whether or not an item is safe, and it is up to the doctor to determine its correct use. While the FDA specifies approval only for treatment of interstitial cystitis this specification has no teeth.